|
|
Gilead Sciences Inc (GILD) |
|
|
|
| |
GILD's Operating Income Growth by Quarter and Year
Gilead Sciences Inc 's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| GILD Operating Income (in millions $) |
FY 2021 |
FY 2020 |
FY 2019 |
FY 2018 |
| IV Quarter |
December |
-
|
2,651.00
|
1,093.00
|
1,144.00
|
| III Quarter |
September |
-
|
2,001.00
|
-1,473.00
|
2,623.00
|
| II Quarter |
June |
-
|
-2,983.00
|
2,430.00
|
2,280.00
|
| I Quarter |
March |
2,890.00
|
2,402.00
|
2,237.00
|
2,153.00
|
| FY |
|
2,890.00
|
4,071.00
|
4,287.00
|
8,200.00
|
| GILD Operating Income first quarter 2021 Y/Y Growth Comment |
Gilead Sciences Inc reported Operating Income improvement of 20.32% year on year in the first quarter, to $ 2,890.00 millions, this is lower than Gilead Sciences Inc 's recent average Operating Income rise of 42.93%.
Looking into first quarter results within Biotechnology & Drugs industry 7 other companies have achieved higher Operating Income growth. While Gilead Sciences Inc ' s Operating Income rise of 20.32% ranks overall at the positon no. 679 in the first quarter.
Explain Operating Income growth
|
| GILD Operating Income ( Y/Y Growth %) |
2021
|
2020 |
2019 |
2018 |
| IV Quarter |
December |
- |
142.54 % |
-4.46 % |
-50.07 % |
| III Quarter |
September |
- |
- |
- |
-31.19 % |
| II Quarter |
June |
- |
- |
6.58 % |
-46.4 % |
| I Quarter |
March |
20.32 % |
7.38 % |
3.9 % |
-42.85 % |
| FY |
|
- |
-5.04 % |
-47.72 % |
-41.94 % |
GILD Operating Income (Quarter on Quarter Growth %) |
2021
|
2020 |
2019 |
2018 |
| IV Quarter |
December |
- |
32.48 % |
- |
-56.39 % |
| III Quarter |
September |
- |
- |
- |
15.04 % |
| II Quarter |
June |
- |
- |
8.63 % |
5.9 % |
| I Quarter |
March |
9.02 % |
119.76 % |
95.54 % |
-6.02 % |
| FY (Year on Year) |
|
- |
-5.04 % |
-47.72 % |
-41.94 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 2136.92 % |
42.93 % |
-48.57 % |
| (Dec. 31, 2007) |
|
(Sep 30 2019) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 2136.92 % |
42.93 % |
-48.57 % |
| (Dec. 31, 2007) |
|
(Sep 30 2019) |
|
| Operating Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021 |
Gilead Sciences Inc 's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 154.18 % |
10.09 % |
-84.25 % |
| (March 31, 2014) |
|
|
| GILD's I. Quarter Q/Q Operating Income Comment |
Gilead Sciences Inc achieved in the I. Quarter 2021 below company average Operating Income increase of 9.02% quarter on quarter, to $ 2,890.00 millions.
Within Biotechnology & Drugs industry 5 other companies have achieved higher Operating Income quarter on quarter growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 633. |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 154.18 % |
10.09 % |
-84.25 % |
| (March 31, 2014) |
|
|
| GILD's I. Quarter Q/Q Operating Income Comment |
Gilead Sciences Inc achieved in the I. Quarter 2021 below company average Operating Income increase of 9.02% quarter on quarter, to $ 2,890.00 millions.
Within Biotechnology & Drugs industry 5 other companies have achieved higher Operating Income quarter on quarter growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 633. |
|
Gilead Sciences Inc 's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Mar 31 2021) |
12 Months Ending
(Dec 31 2020) |
12 Months Ending
(Sep 30 2020) |
12 Months Ending
(Jun 30 2020) |
12 Months Ending
(Mar 31 2020) |
| Cumulative Operating Income 12 Months Ending |
$ 4,559.00 |
$ 4,071.00 |
$ 2,513.00 |
$ -961.00 |
$ 4,452.00 |
| Y / Y Operating Income Growth (TTM) |
2.4 % |
-5.04 % |
-42.07 % |
- |
-46.26 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 843 |
# 735 |
# 933 |
# 0 |
# 1027 |
| Seqeuential Operating Income Change (TTM) |
11.99 % |
62 % |
- |
- |
3.85 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 679 |
# 185 |
# 182 |
# 0 |
# 591 |
| Cumulative Operating Income growth
Comment |
Although Gilead Sciences Inc 's Annual Operating Income growth year on year were below company's average 63.07% , Operating Income announced in the Mar 31 2021 period, show improvement in Operating Income trend, to cumulative trailing twelve month growth of 2.4% year on year, from -5.04% in Dec 31 2020.
In the Healthcare sector 65 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 735 to 843. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
2136.92 % |
42.93 % |
-48.57 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
2464.91 % |
63.07 % |
-91.63 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 8 |
| Sector |
# 43 |
| S&P 500 |
# 679 |
|
| Cumulative Operating Income growth
Comment |
Although Gilead Sciences Inc 's Annual Operating Income growth year on year were below company's average 63.07% , Operating Income announced in the Mar 31 2021 period, show improvement in Operating Income trend, to cumulative trailing twelve month growth of 2.4% year on year, from -5.04% in Dec 31 2020.
In the Healthcare sector 65 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 735 to 843. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
2136.92 % |
42.93 % |
-48.57 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
2464.91 % |
63.07 % |
-91.63 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 8 |
| Sector |
# 43 |
| S&P 500 |
# 679 |
|
34.07%